Last updated: September 6, 2026
Miconazole nitrate, white petrolatum, and zinc oxide are the components of a topical antifungal and skin-barrier formulation associated with Vusion ointment. The product is a mature, niche prescription treatment for candidiasis-associated diaper dermatitis. Its commercial outlook is constrained by low-cost generic and over-the-counter alternatives, limited disease severity, and the absence of meaningful biologic or manufacturing barriers. Public filings do not disclose standalone revenue for the formulation or its individual ingredients.
What drug contains miconazole nitrate, white petrolatum, and zinc oxide?
The best-known U.S. product containing the three ingredients is Vusion ointment. It combines:
| Component |
Function |
| Miconazole nitrate |
Imidazole antifungal active ingredient |
| Zinc oxide |
Skin protectant and moisture barrier |
| White petrolatum |
Occlusive emollient and vehicle |
Vusion is a topical ointment indicated for the adjunctive treatment of diaper dermatitis associated with Candida albicans in patients aged four weeks and older. The formulation contains 0.25% miconazole nitrate, 15% zinc oxide, and approximately 81.35% white petrolatum, according to the FDA prescribing information.[1]
The product is different from common OTC products that contain zinc oxide alone, miconazole alone, or antifungal-plus-barrier combinations prepared by pharmacies or sold under private labels.
What is the FDA regulatory status of the combination?
Vusion was approved in the United States under NDA 21-844. The regulatory pathway was a full new-drug application rather than an abbreviated new-drug application because the branded product was approved as a specific combination and dosage-form product.
| Regulatory characteristic |
Status |
| Product |
Vusion ointment |
| Active drug |
Miconazole nitrate |
| Non-antifungal actives |
Zinc oxide and white petrolatum |
| Dosage form |
Topical ointment |
| U.S. indication |
Candidiasis-associated diaper dermatitis |
| Prescription status |
Prescription product |
| Patient population |
Patients aged four weeks and older |
| FDA pathway |
NDA |
| Biosimilar pathway |
Not applicable |
The regulatory value of the product depends primarily on the approved combination, formulation, labeling, and clinical evidence. Miconazole nitrate itself has long been available in other topical products, including OTC products. Zinc oxide and white petrolatum are established skin-protectant and excipient materials.
FDA labeling instructs caregivers to clean and dry the affected area before application and to apply the ointment at each diaper change. The product is not intended to replace routine diaper-area hygiene or to treat infections outside the labeled indication.[1]
When does miconazole nitrate and zinc oxide exclusivity expire?
The original regulatory exclusivity associated with Vusion is no longer commercially meaningful. The product was approved in the mid-2000s, and any standard five-year new chemical entity exclusivity would have expired years ago. Pediatric exclusivity, if granted in connection with the approval, would also have expired.
The relevant commercial question is patent status. Formulation patents associated with branded topical products generally expire before or during the period in which the active ingredient becomes widely available from other manufacturers. No current exclusivity position comparable to a new chemical entity, orphan-drug product, or biologic reference product exists for this combination.
Does the product have active Orange Book protection?
The Orange Book is the relevant U.S. database for patents and regulatory exclusivity associated with approved prescription drug products.[2] The formulation does not have the profile of a currently protected, high-value Orange Book product. Any historical patents covering Vusion’s formulation, use, or manufacturing process would need to be evaluated against their expiration dates, terminal disclaimers, patent-term adjustments, and listing status.
The commercial exposure is therefore driven by market substitution rather than a pending loss of a large protected franchise. The product should be treated as a mature prescription combination with limited remaining exclusivity value.
What patents protect miconazole nitrate, white petrolatum, and zinc oxide?
Patent protection for the ingredients is weak as a commercial matter.
Miconazole nitrate
Miconazole nitrate is an established imidazole antifungal. Its basic composition-of-matter protection expired long ago. Current patent value, where it exists, would be limited to particular formulations, delivery systems, combinations, manufacturing processes, or new methods of use.
Zinc oxide and white petrolatum
Zinc oxide and white petrolatum are longstanding materials with extensive prior art. Their use as skin-barrier components is technically routine. A patent claim directed broadly to either ingredient would face substantial validity and obviousness challenges. Commercially relevant protection would require a narrow formulation or performance limitation.
Combination formulation
The strongest historical patent position would have been a claim covering the specific ratio of miconazole nitrate, zinc oxide, and petrolatum, together with physical properties such as spreadability, stability, adhesion, or antifungal performance. Such claims can delay direct substitution if they are listed or enforceable, but they do not prevent competitors from selling:
- Miconazole nitrate cream without zinc oxide.
- Zinc oxide barrier ointment without an antifungal.
- Separate antifungal and barrier products.
- A different miconazole concentration or dosage form.
- A non-identical topical formulation supported by its own regulatory pathway.
The combination therefore has a narrower practical moat than a product protected by a composition-of-matter patent.
How many patents cover the formulation?
There is no reliable commercial basis for counting historical patent families as active protection without a current patent and Orange Book review. Patent counts can overstate the strength of a topical product because one invention may generate U.S. continuation, divisional, international, and foreign filings.
For diligence purposes, the relevant categories are:
| Patent category |
Commercial relevance |
| Composition patent |
Low for mature miconazole nitrate |
| Specific formulation patent |
Potentially relevant if unexpired and enforceable |
| Method-of-use patent |
Potentially relevant but limited to the claimed indication |
| Manufacturing-process patent |
Relevant only if difficult to design around |
| Packaging patent |
Usually limited value |
| Device or delivery patent |
Low unless the product uses a specialized applicator |
| Combination patent |
Most relevant historical category |
A patent-number count without claim-chart analysis is not a reliable measure of market protection.
Are there Paragraph IV challenges or generic entry risks?
The formulation faces substantial generic-entry risk because its ingredients are mature, the dosage form is a conventional ointment, and competing products can satisfy much of the same clinical need without reproducing every feature of the branded product.
A Paragraph IV challenge would be relevant only if an ANDA applicant sought to reference an approved prescription product and certified that listed patents were invalid, unenforceable, or would not be infringed. The commercial significance of such a challenge depends on whether active patents remain listed in the Orange Book and whether the applicant can establish pharmaceutical equivalence and therapeutic equivalence.
Generic entry could occur through several routes:
- An ANDA referencing the branded ointment.
- A prescription topical product with miconazole nitrate as the active ingredient.
- OTC products containing miconazole nitrate or zinc oxide.
- Pharmacy-compounded alternatives.
- Separate use of antifungal and barrier products.
The largest competitive threat does not require a direct AB-rated generic. Physicians, pharmacists, and caregivers can substitute across products because the underlying treatment category is familiar and low-cost.
What formulation patents protect the product’s market position?
A formulation patent would be valuable only if it protects a property that materially affects clinical or commercial performance. Relevant claim elements could include:
- A defined miconazole nitrate concentration.
- A specific zinc oxide-to-petrolatum ratio.
- Uniform dispersion of the antifungal in the ointment base.
- Enhanced adhesion to moist or inflamed skin.
- Stability during repeated diaper-change exposure.
- Reduced irritation compared with separate products.
- A manufacturing process that produces consistent particle distribution.
The practical strength of these claims depends on whether competitors can achieve equivalent performance with different excipients or ratios. White petrolatum is widely available, zinc oxide is a commodity material, and miconazole nitrate is sourced by multiple pharmaceutical manufacturers. These conditions reduce manufacturing barriers.
Is biosimilar risk relevant?
Biosimilar risk is not relevant. Miconazole nitrate, zinc oxide, and white petrolatum are small-molecule or nonbiologic materials. The relevant competitive pathways are generic drugs, OTC monograph products, private-label products, and compounded preparations.
There is no reference-biologic exclusivity period, biosimilar interchangeability issue, or biologics patent thicket comparable to products such as adalimumab, ustekinumab, or monoclonal antibodies.
Which companies are challenging the product?
Publicly visible competitive pressure is more likely to come from manufacturers of alternative topical antifungal and diaper-barrier products than from named litigation challengers.
The competitive set includes:
- Manufacturers of generic miconazole nitrate creams and ointments.
- OTC brands selling miconazole products.
- Zinc oxide diaper-rash brands.
- Petroleum-based skin protectants.
- Hospital and pharmacy compounders.
- Private-label retailers.
- Products containing clotrimazole, nystatin, or other topical antifungals.
No high-value, current patent litigation campaign is associated with the combination on the scale seen in protected specialty medicines. The litigation risk is primarily product liability, labeling, infringement, or regulatory compliance risk rather than a major loss-of-exclusivity event.
What is the financial trajectory of the product?
Public companies generally do not report revenue for miconazole nitrate, white petrolatum, and zinc oxide as a separate product line. The formulation is not a major disclosed revenue driver comparable to a branded oncology, immunology, or rare-disease product.
The likely financial trajectory is:
| Period |
Financial profile |
| Launch period |
Premium prescription pricing supported by branded formulation and FDA approval |
| Early commercial period |
Limited niche uptake in candidiasis-associated diaper dermatitis |
| Post-exclusivity period |
Price erosion and substitution by lower-cost antifungal and barrier products |
| Mature period |
Low-volume, low-growth, fragmented category |
| Long-term outlook |
Stable demand for ingredients, limited value in the branded combination |
The underlying ingredients have better volume resilience than the branded combination. White petrolatum and zinc oxide are used across dermatology, wound care, cosmetics, and consumer health. Miconazole nitrate remains commercially relevant in vaginal, dermatologic, and foot-fungus products. This diversification supports ingredient demand even when one prescription combination declines.
What is the revenue exposure?
Revenue exposure is concentrated in:
- Prescription reimbursement for the branded ointment.
- Pharmacy substitution behavior.
- Availability of lower-priced topical antifungals.
- Consumer preference for zinc oxide barrier products.
- Insurance formulary placement.
- Physician willingness to prescribe a combination rather than separate products.
The combination does not have the pricing power associated with an innovative mechanism, a difficult-to-manufacture sterile product, or a clinically differentiated delivery system.
How does the combination compare with competing products?
| Product type |
Antifungal |
Barrier component |
Typical commercial position |
| Vusion-type ointment |
Miconazole nitrate |
Zinc oxide and petrolatum |
Prescription combination |
| Generic miconazole cream |
Miconazole nitrate |
Usually cream excipients |
Low-cost antifungal |
| Zinc oxide ointment |
None |
Zinc oxide and petrolatum |
OTC barrier treatment |
| Nystatin product |
Nystatin |
Varies |
Prescription antifungal |
| Clotrimazole product |
Clotrimazole |
Varies |
OTC or prescription, depending on market |
| Compound therapy |
Variable |
Variable |
Flexible but less standardized |
The combination’s advantage is convenience. Its disadvantage is that many cases can be managed with less expensive single-ingredient products. The product is most defensible when clinicians value simultaneous antifungal and barrier treatment and when the formulation performs better in the presence of moisture and repeated diaper exposure.
What licensing deals affect the product?
No major current licensing transaction is publicly associated with the three-ingredient combination as a standalone asset. Historical ownership or commercialization arrangements may have changed as the branded product moved through corporate portfolios, but the formulation’s mature status limits transaction value.
A potential transaction would more likely concern:
- A broader dermatology portfolio.
- A private-label or contract-manufacturing relationship.
- Rights to a topical formulation platform.
- Regional commercialization rights.
- Manufacturing capacity for miconazole-containing products.
The absence of disclosed product-level revenue makes valuation dependent on prescription volume, net price, reimbursement, manufacturing cost, and remaining regulatory rights.
What generic launch scenarios exist?
Three scenarios are commercially plausible.
Direct AB-rated generic
A direct generic would create the fastest price pressure if it matched the reference formulation and obtained therapeutic-equivalence approval. The impact would be highest in reimbursed prescription channels.
Therapeutic substitution
Generic miconazole, nystatin, or clotrimazole products could capture prescriptions even without an identical three-ingredient formulation. This is the more important long-term threat because clinicians can select products based on diagnosis and formulary cost.
Consumer and pharmacy substitution
Caregivers may use zinc oxide or petrolatum products for uncomplicated irritation and add an OTC antifungal when Candida is suspected. This reduces demand for a premium combination product but may not eliminate demand for antifungal therapy.
What geographic coverage and manufacturing barriers exist?
The ingredients are globally available and supported by mature supply chains. Geographic protection would depend on country-specific registrations, trademarks, formulation patents, and reimbursement status rather than on scarce raw materials.
Manufacturing barriers are modest:
- White petrolatum is widely sourced.
- Zinc oxide is produced at scale.
- Miconazole nitrate is an established active pharmaceutical ingredient.
- Ointment manufacturing does not generally require complex equipment.
- The product is nonsterile and does not require biologic cold-chain handling.
Quality controls remain important. Manufacturers must manage particle dispersion, homogeneity, stability, microbial limits, packaging compatibility, and preservative or contamination risk. Those controls create execution requirements but not a strong exclusionary barrier.
Key Takeaways
- The formulation is principally associated with Vusion ointment.
- Its U.S. regulatory exclusivity is long expired.
- The ingredients are mature and broadly available.
- Patent value is limited to narrow formulation, use, process, or delivery claims.
- Biosimilar risk is irrelevant; generic and OTC substitution are the main threats.
- Direct product-level revenue is not publicly disclosed.
- The branded combination has a niche, mature financial profile rather than a high-growth trajectory.
- White petrolatum, zinc oxide, and miconazole nitrate retain broader demand across dermatology and consumer health.
- Manufacturing complexity is modest, limiting barriers to entry.
- The commercial moat is convenience and combination therapy, not ingredient novelty.
FAQs
Is miconazole nitrate with zinc oxide available over the counter?
Some markets sell antifungal and zinc oxide products separately or in combination, but the regulatory status depends on the country, formulation, concentration, and labeling. A Vusion-type prescription product should not be assumed to have OTC status.
Is Vusion still commercially important?
Vusion is a niche mature product. Its commercial importance is limited by generic miconazole products, zinc oxide barriers, alternative antifungals, and pharmacy substitution.
Can a company patent a new miconazole and zinc oxide ointment?
A new patent may be possible for a genuinely novel and non-obvious formulation, manufacturing process, delivery system, or clinical use. Broad claims to miconazole, zinc oxide, or petrolatum alone would face substantial prior-art challenges.
Does zinc oxide improve miconazole antifungal activity?
Zinc oxide primarily provides a protective barrier and reduces moisture exposure. Any antifungal-performance benefit must be demonstrated for the specific formulation and cannot be inferred solely from the presence of zinc oxide.
Is the formulation suitable for investment as a standalone pharmaceutical asset?
Its standalone value is likely limited. Investment value would depend on established sales, reimbursement, manufacturing economics, geographic rights, and any surviving formulation or trademark protection. The ingredients themselves have broader commercial value than the branded combination.
References
- U.S. Food and Drug Administration. (2006). Vusion ointment prescribing information: Miconazole nitrate, zinc oxide, and white petrolatum.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Approved drug product database.
- U.S. Food and Drug Administration. (2024). Generic drugs and abbreviated new drug applications.
